http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007084507-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1b7bf8146638f617b777ec4c4927917
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00
filingDate 2007-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_869477829d8050d56f579e1658d1728a
publicationDate 2007-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007084507-A3
titleOfInvention [ψ[CH2NH]PG4] GLYCOPEPTIDE ANTIBIOTIC ANALOGS
abstract [ψ[CH2NH]PG4] glycopeptide antibiotic analogs are reengineered forms of glycopeptides that exhibit antimicrobial activity against both wild type and glycopeptide antibiotic resistant strains of microorganisms. For example, [Ψ[CH2NH]Tpg4] vancomycin aglycon is a reengineered form of vancomycin that exhibits antimicrobial activity (MIC = 31 µg/mL) against both wild type and VanA resistant organism (E. faecalis BM4166). The VanA resistant organism achieves its resistance, upon glycopeptide antibiotic challenge, by remodeling its D-Ala-D-Ala peptidoglycan cell wall precursor to D-Ala-D-Lac. [ψ[CH2NH]PG4] glycopeptide antibiotic analogs have an altered glycopeptide backbone wherein the carbonyl of the fourth amino acid residue of the glycopeptide backbone has been replaced with a methylene. This alteration of the glycopeptide backbone imparts dual binding affinities for both D-Ala-D-Ala and D-Ala-D-Lac and dual antimicrobial activities for both wild type and resistant strains. For example, [Ψ[CH2NH]Tpg4]vancomycin aglycon displays a antimicrobial potency that reflects its altered binding characteristics.
priorityDate 2006-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005250677-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6518243-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005080004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5840684-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6953861-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03101393-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005239689-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6962970-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5648456-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6710168-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5571701-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507594
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5651
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16051955
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226419997
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395422
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14969
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419565934
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457814461
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445835
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415968025
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6547
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6992112
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414859283
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395424
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1351
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9816401
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1351

Total number of triples: 46.